ClinicalTrials.gg
CompletedNCT04495283Updated Nov 23, 2021Results posted

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

A Phase 2 interventional study of Pregabalin and Acetaminophen in Postoperative Pain, sponsored by Nevakar, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by Nevakar, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies testing pregabalin in Pain, Postoperative — 7 open to participants now, 7 under way, 1 of them phase 3. Pregabalin · Pain, Postoperative.

Enrollment
38th of 65
87 · median 90
Started
2020
with 4 others
Phase 2
4 of 65
none open now
Registered
50th of 65
by date
Lead sponsor
2 of 65
Nevakar, Inc.

Among the 65 studies testing pregabalin in Pain, Postoperative, this one is the 38th largest by enrollment, is one of 5 that started in 2020, is one of 4 in phase 2, and was the 50th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 65 studies testing pregabalin in Pain, Postoperative are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing pregabalin in Pain, Postoperative, or all of them as a file.
02

Study summary

A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Read the detailed description

A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Up to 80 subjects will be randomized (32 in each active treatment group, 16 placebo).

To evaluate the efficacy of combination pregabalin (PGB) and acetaminophen (APAP) administered vs. placebo for pain control in subjects undergoing bunionectomy.

The placebo will be the saline solution.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide by signing the informed consent form (ICF) approved by the Institutional Review Board (IRB);
  • Be male or female aged 18-65 years;
  • Be scheduled to undergo unilateral first metatarsal bunionectomy;
  • Be in good health and capable of undergoing a bunionectomy under anesthesia as described in the study surgical and anesthetic protocol;
  • Weigh between 50 and 100 kg ( [BMI] \<32 kg/m2);
  • Have no additional planned surgeries other than bunionectomy during the course of the study;
  • Have negative urine drug screen for drugs indicative of illicit drug use (unless results can be explained by a current prescription or acceptable over-the-counter medication at screening as determined by the investigator) and no detectable results on the alcohol test (breath or saliva) indicative of alcohol abuse at screening, and/or prior to surgery (may be repeated if the Investigator suspects a false-positive result). Note: For those subjects who test positive for tetrahydrocannabinol (THC), if they are willing to abstain from use or consumption of THC-containing products from screening through end of the subject's participation in the study, they may be allowed to participate in the study.
  • Biological female subjects must be non-lactating, sterile (bilateral tubal ligation, bilateral salpingectomy, or hysterectomy), for at least 2 years, have a partner that is sterile, be abstinent, use a highly effective double- method (hormonal protection is insufficient), or use an FDA-approved contraceptive for greater than 2 months prior to the screening visit and commit to an acceptable form of birth control for the duration of the study and for 30 days after completion of the study;
  • Be willing and able to complete the study procedures and pain scales and communicate meaningfully in English with study personnel.

Exclusion criteria

Exclusion Criteria:

  • Have a medical condition or history that in the Investigator's opinion could adversely impact the subject's participation or safety or the conduct of the study, or interfere with the pain assessments, including the following:

    1. Serious breathing difficulties or respiratory risk factors (including use of opioid pain medicines and other drugs that depress the central nervous system), and conditions such as that reduce lung function.
    2. Hypertension (uncontrolled), cardiovascular disease, or history of cerebrovascular events. Hypertension must be controlled without known end organ damage.
    3. Concurrent painful conditions that may require analgesic treatment during the study period.
    4. History of significantly reduced hepatic or renal function, angle closure glaucoma, or convulsive disorder.
    5. Recent history of urinary retention.
    6. Opioid tolerant, i.e., the subject is currently taking or has taken a chronic opioid at a dose greater than or equal to 20 mg morphine milligram equivalents (MME) per day (more than 30 consecutive days of daily use) for pain in the 2 months prior to surgery.
    7. Active cutaneous disease, or other disease, at the surgical site.
    8. Peripheral vascular disease, sickle cell disease, vascular grafts, or vasospastic disorders.
    9. Known bleeding disorder or is taking agents affecting coagulation preoperatively.

      Deep venous thrombosis (DVT) prophylaxis of the surgeon's choice is permitted postoperatively.

    10. Diabetes mellitus (uncontrolled). Diabetes mellitus must be controlled without known end organ damage.
    11. History of in the past 2 years with the exception of squamous cell carcinoma or basal cell carcinoma.
    12. Prior bunionectomy on the index foot or other foot surgery on the index foot that could impact the surgery or data collection endpoints.
  • Use of disallowed medications including the following:

    1. Pain medication (opioids, NSAIDs, cyclooxygenase (COX)-2 inhibitors, tramadol, ketamine, clonidine, gabapentin, pregabalin, or cannabinoids) within 2 days prior to Day 1.
    2. Central nervous system (CNS) active drugs such as benzodiazepines, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors (SNRIs), or selective serotonin reuptake inhibitors (SSRIs) for pain within seven days prior to Day 1. These drugs are permitted for non-pain indications if the dose has been stable for at least 30 days prior to Day 1 and is planned to remain stable throughout the study. The use of lorazepam and other sleep medications, except those containing analgesic properties, is permitted.
    3. Use of parenteral or oral (s) within 14 days prior to Day 1.
    4. Antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days, or which is not expected to remain stable throughout the study.
    5. Digoxin, warfarin (see exception below), lithium, theophylline preparations, aminoglycosides, and all antiarrhythmics except beta-blockers, and use of anticonvulsants except benzodiazepines within 7 days prior to Day 1 and throughout the study.
  • Use of warfarin is allowed, at the investigator's discretion, for DVT prophylaxis after the surgery.
  • Significant history of allergic reactions or known intolerance to pregabalin or any gabapentinoid, to APAP, to any rescue medication used in the study, or any medication used in the surgical and anesthetic protocol.
  • Female subjects (biological females only) who are pregnant or lactating, who plan to get pregnant, or who have a positive serum pregnancy test at Screening or a positive urine pregnancy test at either Day -1 or Day 1 prior to surgery.
  • Participated in another clinical trial within 30 days, or previously participated in a clinical study with a similar product.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    PGB and APAP (Group A)

    Group A receives PGB plus APAP prior to surgery and placebo 1 post-surgery.

    Drug: Pregabalin · Drug: Acetaminophen

  • Experimental
    APAP (Group B)

    Group B receives placebo 2 prior to surgery and APAP post-surgery.

    Drug: Acetaminophen · Other: Placebo 2

  • Experimental
    Placebo (Group C).

    Group C receives placebo 1 prior to surgery and placebo 2 post-surgery.

    Other: Placebo 1 · Other: Placebo 2

Interventions

  • Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.

    Also known as: PGB

  • Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.

    Also known as: APAP

  • OtherPlacebo 1

    Placebo for APAP

  • OtherPlacebo 2

    Placebo for combination

06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity (SPI) Between Group A and Group C

    Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, was used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: Sum (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and placebo (Group C) from Hour 0 to Hour 48 (SPI0-48)

    Time frame: 0 to 48 hours

Secondary outcomes

  1. Summed Pain Intensity (SPI) Compared Between Group A and Group B

    Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) -was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and APAP alone (Group B) from Hour 0 to Hour 48 (SPI0-48)

    Time frame: 0 to 48 hours

  2. Summed Pain Intensity (SPI) Assessed by Numeric Rating Scale From Hour 0 to Hour 12 (SPI0-12), Hour 12 to Hour 24 (SPI12-24), and Hour 24 to Hour 48 (SPI24-48).

    Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals at 0-12, 12-24 and 24-48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time interval (0-12, 12-24 and 24-48 hours). This outcome was compared between a combination of PGB and APAP, APAP alone, and placebo.

    Time frame: 0, 12, 24, 48 hours

  3. Summed Pain Intensity (SPI) Assessed by Numeric Rating Scale Over Time

    Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals from 0 hour till each time point at 1, 2, 4, 6, 8, 10 ,12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, and 48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time intervals.

    Time frame: 0, 1, 2, 4, 6, 8, 10 ,12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, and 48 hours

  4. Number of Participants With Treatment-Related Adverse Events (TRAE)

    A TRAE is defined as a treatment-emergent adverse event (TEAE) that was classified by the investigator as related to study drug. The number of participants with TRAE were reported

    Time frame: 7 days

  5. Percentage of Participants Who Were Opioid Free Over Time

    Percentages of participants who did not take opioid (rescue medication) over time.

    Time frame: 12 to 48 hours

  6. Total Consumption of Opioid Rescue Medication Through 24 Hours and 48 Hours

    The total consumption of opioid rescue analgesia through 24 hours and through 48 hours was reported

    Time frame: 24 hours and 48 hours

  7. Total Consumption of Rescue Medication

    The total consumption of rescue analgesia was reported.

    Time frame: 7 days

  8. Time to First Use of Rescue Medication From Hour 0

    Time to first use of rescue medication from Hour 0 was reported. Hour 0 was defined as the end of surgery (i.e., completion of the last suture).

    Time frame: 7 days

  9. Percentage of Participants Who Used Rescue Medication

    Percentage of participants who used rescue medication is reported

    Time frame: 7 days

  10. Patient Global Assessment of Pain

    Patient Global Assessment (PGA) of pain control at 48 hours was reported. Patient global evaluation will be self-reported over 24 hours, using a 0-4 categorical rating scale of: (0) poor, (1) fair, (2) good, (3) very good, and (4) excellent

    Time frame: 48 hours

  11. Maximum Observed Concentration for PGB and APAP

    The Plasma Concentration (Cmax) is defined as the maximum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.

    Time frame: Pre-infusion (at least 3.0 minutes before the start of the first infusion) and at 0.5, 1.5, 6.0, 8.0, 12.0, 16.0, 18.0, 24.0, 30.0, 32.0, 36.0, 40.0, 42.0, and 48 hours post-infusion

  12. Minimum Observed Concentration for PGB and APAP

    The Plasma Concentration (Cmin) is defined as the minimum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.

    Time frame: Pre-infusion (at least 3.0 minutes before the start of the first infusion) and at 0.5, 1.5, 6.0, 8.0, 12.0, 16.0, 18.0, 24.0, 30.0, 32.0, 36.0, 40.0, 42.0, and 48 hours post-infusion

07

Results

Posted Nov 23, 2021

Participant flow

Participants were recruited from 28 July 2020 till 26 Oct 2020 across the sites.

Participant flow — Overall Study
MilestonePGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Started353517
Completed343414
Not completed113
Withdrew: Physician decision001
Withdrew: Withdrawal by subject011
Withdrew: Other101

Outcome measures

PrimarySummed Pain Intensity (SPI) Between Group A and Group C

Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, was used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: Sum (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and placebo (Group C) from Hour 0 to Hour 48 (SPI0-48)

Time frame:
0 to 48 hours
Reported as:
Least squares mean · score on a scale
Summed Pain Intensity (SPI) Between Group A and Group C
score on a scalePGB and APAP (Group A)Placebo (Group C).
Summed Pain Intensity (SPI) Between Group A and Group C153.08 ± 15.238267.51 ± 21.864
Statistical analysis
  • PGB and APAP (Group A) vs Placebo (Group C). · ANOVA · p = <0.001 · Ls mean difference: -114.43
SecondarySummed Pain Intensity (SPI) Compared Between Group A and Group B

Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) -was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and APAP alone (Group B) from Hour 0 to Hour 48 (SPI0-48)

Time frame:
0 to 48 hours
Reported as:
Least squares mean · score on a scale
Summed Pain Intensity (SPI) Compared Between Group A and Group B
score on a scalePGB and APAP (Group A)APAP (Group B)
Summed Pain Intensity (SPI) Compared Between Group A and Group B153.08 ± 15.238223.24 ± 5.238
Statistical analysis
  • PGB and APAP (Group A) vs APAP (Group B) · ANOVA · p = <0.001 · Ls mean difference: -70.16
SecondarySummed Pain Intensity (SPI) Assessed by Numeric Rating Scale From Hour 0 to Hour 12 (SPI0-12), Hour 12 to Hour 24 (SPI12-24), and Hour 24 to Hour 48 (SPI24-48).

Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals at 0-12, 12-24 and 24-48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time interval (0-12, 12-24 and 24-48 hours). This outcome was compared between a combination of PGB and APAP, APAP alone, and placebo.

Time frame:
0, 12, 24, 48 hours
Reported as:
Least squares mean · score on a scale
Summed Pain Intensity (SPI) Assessed by Numeric Rating Scale From Hour 0 to Hour 12 (SPI0-12), Hour 12 to Hour 24 (SPI12-24), and Hour 24 to Hour 48 (SPI24-48).
score on a scalePGB and APAP (Group A)APAP (Group B)Placebo (Group C).
SPI 0-1233.09 ± 3.72849.09 ± 3.72858.89 ± 5.349
SPI 12-2450.92 ± 5.08269.35 ± 5.08288.95 ± 7.292
SPI 24-48126.83 ± 13.128184.33 ± 13.128221.58 ± 18.837
SecondarySummed Pain Intensity (SPI) Assessed by Numeric Rating Scale Over Time

Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals from 0 hour till each time point at 1, 2, 4, 6, 8, 10 ,12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, and 48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time intervals.

Time frame:
0, 1, 2, 4, 6, 8, 10 ,12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, and 48 hours
Reported as:
Mean · score on a scale
Summed Pain Intensity (SPI) Assessed by Numeric Rating Scale Over Time
score on a scalePGB and APAP (Group A)APAP (Group B)Placebo (Group C).
SPI 0-10.26 ± 0.5090.73 ± 0.8700.45 ± 0.951
SPI 0-21.26 ± 1.5912.39 ± 2.5392.16 ± 2.560
SPI 0-45.63 ± 5.1208.02 ± 6.7039.62 ± 6.196
SPI 0-612.68 ± 9.65017.09 ± 10.60620.71 ± 10.368
SPI 0-820.00 ± 14.21128.09 ± 14.26633.64 ± 14.203
SPI 0-1026.25 ± 18.41338.71 ± 18.14045.95 ± 18.510
SPI 0-1233.09 ± 22.72549.09 ± 21.69258.89 ± 21.362
SPI 0-1441.12 ± 27.03558.62 ± 25.00972.17 ± 24.820
SPI 0-1649.08 ± 30.48067.98 ± 27.40184.46 ± 27.487
SPI 0-1855.84 ± 33.98578.49 ± 31.84797.57 ± 32.420
SPI 0-2061.49 ± 36.25986.24 ± 35.453108.32 ± 37.011
SPI 0-2477.17 ± 43.864108.25 ± 43.928134.91 ± 42.035
SPI 0-2888.94 ± 50.680128.83 ± 52.561158.01 ± 45.579
SPI 0-32100.85 ± 56.483148.93 ± 59.923180.50 ± 54.648
SPI 0-36114.43 ± 63.776169.44 ± 67.178203.32 ± 64.342
SPI 0-40126.45 ± 69.998186.70 ± 73.308224.78 ± 72.951
SPI 0-44139.54 ± 78.396199.95 ± 78.945246.09 ± 84.178
SPI 0-48153.08 ± 87.398223.24 ± 91.581267.51 ± 92.791
SecondaryNumber of Participants With Treatment-Related Adverse Events (TRAE)

A TRAE is defined as a treatment-emergent adverse event (TEAE) that was classified by the investigator as related to study drug. The number of participants with TRAE were reported

Time frame:
7 days
Reported as:
Number · participants
Number of Participants With Treatment-Related Adverse Events (TRAE)
participantsPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Number of Participants With Treatment-Related Adverse Events (TRAE)2297
SecondaryPercentage of Participants Who Were Opioid Free Over Time

Percentages of participants who did not take opioid (rescue medication) over time.

Time frame:
12 to 48 hours
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Opioid Free Over Time
percentage of participantsPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
During 12-24 Hours65.745.735.3
During 12-48 Hours48.628.629.4
SecondaryTotal Consumption of Opioid Rescue Medication Through 24 Hours and 48 Hours

The total consumption of opioid rescue analgesia through 24 hours and through 48 hours was reported

Time frame:
24 hours and 48 hours
Reported as:
Mean · oral morphine equivalents
Total Consumption of Opioid Rescue Medication Through 24 Hours and 48 Hours
oral morphine equivalentsPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Consumption of Rescue Medication through 24 hours9.86 ± 14.13419.24 ± 17.01928.88 ± 20.981
Consumption of Rescue Medication through 48 hours17.36 ± 21.79633.39 ± 30.84743.88 ± 32.419
SecondaryTotal Consumption of Rescue Medication

The total consumption of rescue analgesia was reported.

Time frame:
7 days
Reported as:
Mean · oral morphine equivalents
Total Consumption of Rescue Medication
oral morphine equivalentsPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Total Consumption of Rescue Medication17.79 ± 22.34434.24 ± 32.49644.76 ± 33.609
SecondaryTime to First Use of Rescue Medication From Hour 0

Time to first use of rescue medication from Hour 0 was reported. Hour 0 was defined as the end of surgery (i.e., completion of the last suture).

Time frame:
7 days
Reported as:
Median · hours
Time to First Use of Rescue Medication From Hour 0
hoursPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Time to First Use of Rescue Medication From Hour 011.60 (5.93 to 16.12)5.78 (4.27 to 7.97)4.31 (3.57 to 5.87)
SecondaryPercentage of Participants Who Used Rescue Medication

Percentage of participants who used rescue medication is reported

Time frame:
7 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Used Rescue Medication
percentage of participantsPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Percentage of Participants Who Used Rescue Medication57.180.082.4
SecondaryPatient Global Assessment of Pain

Patient Global Assessment (PGA) of pain control at 48 hours was reported. Patient global evaluation will be self-reported over 24 hours, using a 0-4 categorical rating scale of: (0) poor, (1) fair, (2) good, (3) very good, and (4) excellent

Time frame:
48 hours
Reported as:
Count of participants · Participants
Patient Global Assessment of Pain
ParticipantsPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
(0) Poor111
(1) Fair477
(2) Good673
(3) Very good10103
(4) Excellent1491
SecondaryMaximum Observed Concentration for PGB and APAP

The Plasma Concentration (Cmax) is defined as the maximum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.

Time frame:
Pre-infusion (at least 3.0 minutes before the start of the first infusion) and at 0.5, 1.5, 6.0, 8.0, 12.0, 16.0, 18.0, 24.0, 30.0, 32.0, 36.0, 40.0, 42.0, and 48 hours post-infusion
Reported as:
Geometric mean · nanogram per milliliter (ng/ml)
Maximum Observed Concentration for PGB and APAP
nanogram per milliliter (ng/ml)PGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Mean Cmax Values of Pregabalin- First Dose10068 ± 36——
Mean Cmax Values of Pregabalin- Last Dose12960 ± 27——
Mean Cmax Values of Acetaminophen-First Dose28700 ± 3416847 ± 39—
SecondaryMinimum Observed Concentration for PGB and APAP

The Plasma Concentration (Cmin) is defined as the minimum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.

Time frame:
Pre-infusion (at least 3.0 minutes before the start of the first infusion) and at 0.5, 1.5, 6.0, 8.0, 12.0, 16.0, 18.0, 24.0, 30.0, 32.0, 36.0, 40.0, 42.0, and 48 hours post-infusion
Reported as:
Geometric mean · nanogram per milliliter (ng/ml)
Minimum Observed Concentration for PGB and APAP
nanogram per milliliter (ng/ml)PGB and APAP (Group A)APAP (Group B)Placebo (Group C).
Minimum Observed Concentration for PGB and APAPNA ± NANA ± NA—

Adverse events

Collected over Up to 7 days (± 1 day). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PGB and APAP (Group A)0/35 (0%)0/35 (0%)27/35 (77.1%)
APAP (Group B)0/35 (0%)0/35 (0%)15/35 (42.9%)
Placebo (Group C).0/17 (0%)0/17 (0%)9/17 (52.9%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPGB and APAP (Group A)APAP (Group B)Placebo (Group C).
DizzinessNervous system disorders18/353/353/17
NauseaGastrointestinal disorders9/355/355/17
VomitingGastrointestinal disorders5/352/354/17
HeadacheNervous system disorders3/352/352/17
Application site rashGeneral disorders0/350/351/17
Injection site extravasationGeneral disorders2/350/351/17
Pain in extremityMusculoskeletal and connective tissue disorders0/350/351/17
BlisterSkin and subcutaneous tissue disorders0/350/351/17
Transaminases increasedInvestigations2/352/350/17
TachycardiaCardiac disorders0/351/350/17

Baseline characteristics

The Safety Analysis Set included all subjects who received any amount of study drug (APAP + PGB, APAP, or placebo), whether or not they were prematurely withdrawn from the study.

Age, Continuous
Age, Continuous(years)PGB and APAP (Group A)APAP (Group B)Placebo (Group C).Total
Mean43.7 ± 13.3342.1 ± 11.6843.3 ± 11.9843.0 ± 12.31
Sex: Female, Male
Sex: Female, Male(Participants)PGB and APAP (Group A)APAP (Group B)Placebo (Group C).Total
Female25311773
Male104014
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PGB and APAP (Group A)APAP (Group B)Placebo (Group C).Total
Hispanic or Latino912728
Not Hispanic or Latino26231059
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PGB and APAP (Group A)APAP (Group B)Placebo (Group C).Total
American Indian or Alaska Native1012
Asian1203
Native Hawaiian or Other Pacific Islander0000
Black or African American77418
White24261262
More than one race2002
Unknown or Not Reported0000
Body Mass Index
Body Mass Index(kg/m^2)PGB and APAP (Group A)APAP (Group B)Placebo (Group C).Total
Mean26.03 ± 3.21326.55 ± 3.47126.05 ± 3.40626.24 ± 3.326
08

Study locations

2 sites
  • Lotus Clinical Resarch,LLC
    Pasadena, California 91105, United States
  • Lotus HD Research
    Bellaire, Texas 77401, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2020, 3 months.

Results were first posted in Nov 2021, 1 year after primary completion.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2020
First posted
Jul 31, 2020
StartActual
Jul 28, 2020
Primary completionActual
Nov 12, 2020
CompletionActual
Nov 12, 2020
Results first posted
Nov 23, 2021
Last update
Nov 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04495283
Lead sponsor
Nevakar, Inc.
Collaborators
Nevakar Injectables, Inc.
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Jul 28, 2020
Primary completion
Nov 12, 2020
Completion
Nov 12, 2020
Results posted
Nov 23, 2021
Last update
Nov 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Acetaminophen

Start the discussion